About
Targeting the Nervous System
Neuralstem (NASDAQ:CUR) is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. Our lead asset, NSI-189, is a new chemical entity in Phase 2 clinical development for major depressive disorder (MDD). Our lead stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). These product candidates are based on the company’s proprietary neural stem cell technology.
Three Proprietary Technologies
We have three proprietary technologies: The small molecule program, the stem cell therapy program, and a new chemical entity screening platform.
The company’s proprietary methodology enables the generation and commercial-scale production of regionally specific neural stem cell lines for use in therapeutic indications or drug screening. This platform enables high content screening of compound libraries for discovery of novel CNS-targeted compounds, and led to the discovery of NSI-189, our lead compound.
